Pediococcus acidilactici R037 for Allergy and Lipid Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases and lifestyle diseases such as hay fever, atopic dermatitis, and hyperlipidemia often come with side effects and are difficult to maintain, while existing lactic acid bacteria preparations lack sufficient antiallergic and neutral fat-lowering effects.
Innovation Solution
A novel strain of Pediococcus acidilactici R037 and its variants, which exhibit excellent antiallergic, neutral fat-lowering, and anti-autoimmune disease functions, are used in compositions for pharmaceutical, health food, or dietary supplement forms to prevent or ameliorate these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (antihistamine agents, steroidal agents) are used for allergic diseases, then allergy symptoms are relieved, but side effects and safety issues occur
Solution Approach 1:
The patent uses lactic acid bacteria as a biological intermediary to modulate the immune system and reduce IgE antibody production, providing an alternative mechanism that avoids the direct pharmacological intervention causing side effects. The bacteria act as a mediator between the allergen exposure and immune response, fundamentally changing the treatment approach from symptom suppression to immune system regulation.
2Reliability
If diet therapy and exercise therapy are used for hyperlipidemia, then neutral fat level is lowered, but patient compliance is difficult to maintain
Solution Approach 1:
The lactic acid bacteria preparation enables the body to perform fat metabolism regulation automatically through biological mechanisms. The bacteria colonize the gastrointestinal tract and continuously exert their neutral fat-lowering effect without requiring active patient participation in diet control or exercise routines, thus achieving self-service health management.
3Reliability
If existing lactic acid bacteria preparations are used, then some health effects are achieved, but antiallergic and neutral fat-lowering effects are insufficient
Solution Approach 1:
The patent identifies and utilizes specific strains of lactic acid bacteria (Pediococcus acidilactici and related species) with optimized biological parameters for enhanced antiallergic and neutral fat-lowering activities. The selection criteria include specific fermentation capabilities, immune modulation properties, and metabolic characteristics that differentiate these strains from conventional lactic acid bacteria used in existing preparations.
Data Source
AI summary
The present invention provides very safe lactic acid bacteria and lactic acid bacteria preparations which are effective in prevention and therapy of allergies and/or in lowering of the blood neutral fat level. The present invention also provides pharmaceutical products and food or drink products which contain, as an active ingredient, a composition that contains cultured cells of the lactic acid bacterium Pediococcus acidilactici R037 or a treated product thereof.